Oral GLP-1 drug shows promise for adults with diabetes and obesity
Orforglipron , an investigative and oral GLP-1 drug, appears to enable adults with obesity and Type 2 diabetes to achieve significantly more weight loss and improvement in blood […]
ADVERTISMENT
Orforglipron , an investigative and oral GLP-1 drug, appears to enable adults with obesity and Type 2 diabetes to achieve significantly more weight loss and improvement in blood […]
New research is uncovering how medications targeting the glucagon-like peptide-1 (GLP-1) system affect brain circuits involved in nausea, thirst, and pleasurable behaviors. These findings will be presented at […]
A new analysis of the SELECT trial – the largest and longest clinical trial to date examining the cardiovascular benefits of semaglutide (a medication used to support weight […]
Calorie labelling, which became law in April 2022 in England, is associated with only a small (2%) average reduction in the energy content of food that is available […]
Soaring demand for GLP-1 receptor agonists, commonly prescribed for diabetes and obesity, is driving a surge in the online sale of illegal medicines. The European Medicines Agency (EMA) […]
GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting […]
The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight. However, a new population-wide study being presented at […]
Researchers report that patients with psoriasis treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) have achieved a 78% reduced risk of death and a 44% reduced risk of major […]
Adding the novel medication baxdrostat to standard care may help manage high blood pressure and delay the progression of kidney disease in people with chronic kidney disease and […]
Less than half of England has access to tirzepatide (Mounjaro) through their GP, despite the NHS roll-out of the weight-loss jab officially starting over two months ago, an […]
Worldwide, 60 million people suffer from heart failure (HF). Heart failure with preserved ejection fraction (HFpEF) is the most common form of HF, especially among people with obesity […]
New research has found that the use of GLP-1 receptor agonists*, a class of medications commonly prescribed for patients with obesity and diabetes, reduces the environmental footprint of […]
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.